SCHEMBL24399688

SCHEMBL24399688

Cc1ccc2c(Nc3ccc(F)cc3F)nccc2c1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.44
FLT1 P17948 1/20 0.44
KDR P35968 1/20 0.44
ALDH1A1 P00352 2/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
MAPT P10636 1/20 0.39
CLK1 P49759 1/20 0.39
FERMT2 Q96AC1 1/20 0.39
RAF1 P04049 1/20 0.38
BRAF P15056 1/20 0.38
PIM1 P11309 2/20 0.38
PIM2 Q9P1W9 2/20 0.38
FLT3 P36888 1/20 0.38
PIM3 Q86V86 1/20 0.38
MAPK14 Q16539 3/20 0.38
DYRK1A Q13627 1/20 0.37
MAPK1 P28482 1/20 0.37
NPC1 O15118 1/20 0.36
CCNC P24863 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24399762 0.90 DHFR (0.40) FGFR1FLT1KDRALDH1A1CACNA1B
SCHEMBL26210494 0.90 HDAC3 (0.44) FGFR1FLT1KDRALDH1A1RAF1
SCHEMBL26207944 0.88 KDR (0.46) FGFR1FLT1KDRALDH1A1RAF1
SCHEMBL24399714 0.87 EGFR (0.36) FGFR1FLT1KDRALDH1A1CACNA1B
SCHEMBL29638638 0.87 EGFR (0.36) FGFR1FLT1KDRALDH1A1CACNA1B
SCHEMBL26208965 0.85 DYRK1A (0.43) FGFR1FLT1KDRCLK1FERMT2
SCHEMBL24399737 0.84 KDR (0.40) FGFR1FLT1KDRRAF1BRAF
SCHEMBL30402491 0.84 KDR (0.40) FGFR1FLT1KDRRAF1BRAF
SCHEMBL24399572 0.84 RAPGEF4 (0.40) KDRALDH1A1RAF1BRAFMAPK14
SCHEMBL26207960 0.84 LRRK2 (0.48) FGFR1FLT1KDRALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 EP disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 EP disclosed
WO-2022089219-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF AHR, ARNT, NOTUM FGFR1 256/4885FLT1 1194/4885KDR 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.